FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BEN	IEFICIAL	OWNERS	SHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average bu	ırden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						- 7	()				j								
Name and Address of Reporting Person* Jaw Ching			2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [CYTK]								(Ch	eck all applic	tionship of Reporting F all applicable) Director		10% Ov	vner			
(Last) 280 EAS	•	(First) (Middle) GRAND AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 03/06/2020									below)			below)	<i>'</i>
	reet) DUTH SAN RANCISCO CA 94080				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Addividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																
			ole I - Nor			_			-	Dis	_				_				7. No. 100
1. Title of Security (Instr. 3) 2. Trans Date (Month/				Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code		4. Securities Acquired (Disposed Of (D) (Instr. 3 5)			Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)		Price			Transact		(111311.4)	
Common Stock 03/06					5/202	/2020		A		30,00	30,000 A		\$0.0	73,1	73,165 ⁽¹⁾		D		
			Table II -						uired, C s, optior						Owned			,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	ransaction ode (Instr.				6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		expiration Pate	Title	OI N O	umber					
Incentive Stock Option (right to buy)	\$14.4	03/06/2020			A		9,592		(2)	0	3/05/2030	Comm		,592	\$14.4	9,592		D	
Non- Qualified Stock Option (right to buy)	\$14.4	03/06/2020			A		50,408		(2)	0	3/05/2030	Comm		0,408	\$14.4	50,408	3	D	

Explanation of Responses:

- 1. Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.
- 2. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

By: John Faurescu, Esq. For: **Ching Jaw**

03/09/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.